New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Alunbrig brigatinib Click here for more information |
Ariad Pharm. | A kinase inhibitor for a certain type of non-small cell lung cancer. |
|
Austedo deutetrabenazine Click here for more information |
Teva | A VMAT2 inhibitor for chorea associated with Huntington's disease. |
|
Bavencio avelumab Click here for more information |
EMD Serono | A monoclonal antibody for metastatic Merkel cell carcinoma and urothelial carcinoma. |
|
Baxdela delafloxacin Click here for more information |
Melinta Therapeutics | A fluoroquinolone antibiotic for acute bacterial skin/skin structure infections. |
|
Bevyxxa betrixaban Click here for more information |
Portola Pharm. | A factor Xa inhibitor for prophylaxis of venous thromboembolism (VTE) due to restricted mobility or other VTE risk factors during hospitalization. |
|
Brineura cerliponase alfa Click here for more information |
BioMarin | An enzyme replacement therapy to slow loss of walking ability in pediatric patients with a form of Batten disease. |
|
Dupixent dupilumab Click here for more information |
Regeneron | An IL-4RA antagonist for moderate to severe eczema (atopic dermatitis). |
|
Emflaza deflazacort Click here for more information |
Marathon Pharm. | An oral corticosteroid for Duchenne muscular dystrophy. |
|
Haegarda C1 esterace inhibitor |
CSL Behring | A C1 esterace inhibitor (human) to prevent hereditary angioedema attacks. |
|
Idhifa enasidenib Click here for more information |
Celgene | An oral isocitrate dehydrogenase-2 inhibitor for acute myeloid leukemia. |
|
Imfinzi durvalumab Click here for more information |
AstraZeneca | A monoclonal antibody for advanced or metastatic urothelial carcinoma. |
|
Ingrezza valbenazine Click here for more information |
Neurocrine Biosciences | A VMAT2 inhibitor for adults with tardive dyskinesia. |
|
Kevzara sarilumab Click here for more information |
Sanofi-Aventis | An IL-6 receptor antagonist for moderate to severe rheumatoid arthritis. |
|
Kisqali ribociclib Click here for more information |
Novartis | A kinase inhibitor for postmenopausal women with advanced breast cancer. |
|
Mavyret glecaprevir/pibrentasvir Click here for more information |
AbbVie | A fixed-dose combination tablet for chronic hepatitis C infection. |
|
Nerlynx neratinib Click here for more information |
Puma Biotechnology | An oral kinase inhibitor extended adjuvant therapy for breast cancer. |
|
Ocrevus ocrelizumab Click here for more information |
Genentech | A monoclonal antibody for relapsing or primary progressive forms of multiple sclerosis. |
|
Odactra house dust mite allergen extract Click here for more information |
Merck | A sublingual tablet allergen extract for house dust mite-induced allergic rhinitis. |
|
Parsabiv etelcalcetide Click here for more information |
Amgen | A calcium-sensing receptor agonist for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. |
|
Radicava edaravone Click here for more information |
MT Pharma America | An intravenous treatment for amyotrophic lateral sclerosis (ALS). |
|
Rebinyn Factor IX, glycoPEGylated |
Novo Nordisk | A coagulation factor for management of bleeding in patients with hemophilia B. |
|
Renflexis infliximab-abda Click here for more information |
Merck | A biosimilar to Remicade for multiple indications. |
|
Rituxan Hycela rituximab/hyaluronidase Click here for more information |
Genentech | New formulation for certain lymphomas and chronic lymphocytic leukemia. |
|
Rydapt midostaurin Click here for more information |
Novartis | A kinase inhibitor for patients with acute myeloid leukemia (AML) and other rare blood disorders. |
|
Siliq brodalumab Click here for more information |
Valeant | An IL-17RA antagonist for moderate to severe plaque psoriasis. |
|
Symproic naldemedine Click here for more information |
Shionogi | An opioid antagonist for opioid-induced constipation. |
|
Tremfya guselkumab Click here for more information |
Janssen Biotech | An IL-23 antagonist for moderate to severe plaque psoriasis. |
|
Trulance plecanatide |
Synergy Pharm. | A guanylate cyclase-C agonist for chronic idiopathic constipation. |
|
Tymlos abaloparatide Click here for more information |
Radius Health | A human parathyroid hormone related peptide analog for postmenopausal women with osteoporosis and high fracture risk. |
|
Vosevi sofosbuvir/velpatasvir/voxilaprevir Click here for more information |
Gilead Sciences | An oral fixed-dose combination product for chronic hepatitis C infection. |
|
Xadago safinamide Click here for more information |
US WorldMeds | An MAO-B inhibitor for Parkinson's patients experiencing "off" episodes. |
|
Xermelo telotristat Click here for more information |
Lexicon Pharm. | An oral tryptophan hydroxylase inhibitor for carcinoid syndrome diarrhea. |
|
Zejula niraparib Click here for more information |
Tesaro | A PARP inhibitor for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Airduo Respiclick fluticasone/salmeterol Click here for more information |
Teva | New oral inhalation combination corticosteroid and LABA for treatment of asthma. |
|
Armonair Respiclick fluticasone Click here for more information |
Teva | New oral inhalation corticosteroid for maintenance treatment of asthma. |
|
Arymo ER morphine Click here for more information |
Egalet US | New extended-release tablets for severe pain. |
|
Corphedra ephedrine Click here for more information |
Par | New injectable formulation for treatment of hypotension during anesthesia. |
|
Cotempla XR-ODT methylphenidate Click here for more information |
Neos Therapeutics | New extended-release orally disintegrating tablet formulation for ADHD. |
|
Endari L-glutamine Click here for more information |
Emmaus Medical | New oral powder formulation to reduce complications associated with sickle cell disease. |
|
Gleolan aminolevulinic acid hydrochloride Click here for more information |
NXDC | New oral solution formulation optical imaging agent. |
|
Jadenu Sprinkle deferasirox Click here for more information |
Novartis | New sprinkle granules formulation for treatment of chronic iron overload. |
|
Minolira minocycline |
Promius Pharma | New extended-release tablet formulation for non-nodular moderate to severe acne. |
|
Mydayis amphetamine, mixed salts Click here for more information |
Shire US | New CNS stimulant formulation for ADHD. |
|
Nityr nitisinone Click here for more information |
Cycle Pharm. | New tablet formulation for hereditary tyrosinemia type 1. |
|
Noctiva desmopressin Click here for more information |
Allergan | New nasal spray formulation for nocturia due to nocturnal polyuria. |
|
Qtern dapagliflozin/saxagliptin Click here for more information |
AstraZeneca | A new combination SGLT-2 inhibitor and DPP-4 inhibitor for type 2 diabetes. |
|
Rhofade oxymetazoline Click here for more information |
Allergan | New topical cream formulation for facial erythema associated with rosacea. |
|
Roxybond oxycodone Click here for more information |
Inspirion Delivery Sciences | A new opioid analgesic formulation for management of severe pain. |
|
Symjepi epinephrine Click here for more information |
Adamis Pharm. | New pre-filled syringe injection formulation for emergency treatment of allergic reactions. |
|
Tepadina thiotepa Click here for more information |
Adienne | New injectable formulation for intravenous, intracavitary, or intravesical use. |
|
Triptodur triptorelin Click here for more information |
Arbor Pharm. | New extended-release IM formulation for central precocious puberty. |
|
Vantrela ER hydrocodone Click here for more information |
Teva | New extended-release tablets for severe pain. |
|
Vyxeos daunorubicin/cytarabine Click here for more information |
Jazz Pharm. | New liposomal combination formulation for certain types of acute myeloid leukemia. |
|
Xatmep methotrexate Click here for more information |
Silvergate Pharm. | New oral solution formulation for pediatric patients with acute lymphoblastic leukemia (ALL) and juvenile arthritis. |
|
Zerviate cetirizine Click here for more information |
Nicox Ophthalmics | New ophthalmic solution (0.24%) formulation for ocular itching associated with allergic conjunctivitis. |
|
Zypitamag pitavastatin Click here for more information |
Zydus Pharm. | New magnesium salt formulation of pitavastatin for hyperlipidemia. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Opana ER oxymorphone |
Endo | Withdrawal from the market requested by the FDA due to concern the benefits of the drug no longer outweigh its risks. |